17,261 trials
HIV Infections
Primary: The Proportion of Women Who Develop One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay in Plasma (Sampling…
Metastatic Melanoma · Metastatic Kidney Cancer
Primary: Objective Response — 0; 0; 0; 0 Participants
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Multiple Sclerosis
Primary: Overview of Adverse Events [AE] — 35; 33; 32; 1 participants
Multiple Sclerosis
Primary: Overview of Adverse Events (AE] — 32; 35; 35; 3 participants
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Lymphoma
Primary: Progression-free Survival — 90 percentage of participants
Cancer
Primary: Part A: Area Under Plasma Concentration-time Curve (AUC) — 1920; 2392 ng*h/mL
Familial Mediterranean Fever
Primary: To Assess the Efficacy of Rilonacept in Decreasing the Number of Acute FMF Attacks. — 0.77; 2.00 number of attacks per month — p=0.027
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Type 1 Diabetes Mellitus
Primary: C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) at 12 Months — 0.451; 0.371 pmol/ml
Mycosis Fungoides
Primary: Ratio of Response Rates Based on CAILS — 76; 62 percentage of participants
Asthma
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve 0-24 Hours (AUC0-24h) Response — 0.091; 0.241; 0.250 L — p=<0.0001
Multiple Sclerosis
Primary: Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core) — 2.3; 1.4; 0.4 GD- enhanced T1 lesions
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants